Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot Wounds

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80 years.~2. Type 1 or Type 2 diabetes mellitus (with any kind or combination of pharmacological treatment for disease and/or complications to disease).~3. HbA1c ≤ 97 mmol/mol (≤ 11%).~4. Males or non-pregnant females.~5. Understand trial information document.~6. Provide written informed consent.~7. Duration of (diabetic foot) wound \> 4 but \< 52 weeks.~8. Reduction of \< 50% area over 4 weeks despite standard care (standard care; off-loading, weekly debridement, dressings, orthotic).~9. Wound area with sharp debridement of ≥ 0.5 but ≤ 4.0 cm2.~10. Clinically non-infected wound.~11. Texas wound stage 1a, 1c or 2a.~12. Location of wound below malleolus.~13. Affected limb toe pressure ≥ 40 mmHg.~14. An ankle-brachial systolic pressure index between 0.7 and 1.3.~15. Diagnosis of peripheral neuropathy using American Diabetes Association guidelines (monofilament/vibration sensation/biothesiometer).~16. Able to adhere to study visit protocol.~17. Adhere to offloading devices/orthotic.~Exclusion Criteria:~1. Life expectancy of less than 12 months.~2. Patients with a definite diagnosis of any immunodeficiency disorder.~3. Viral hepatitis \[patient must have negative hepatitis B surface-antigen (HBsAg) and hepatitis C antibody (HepCAb) test results obtained within 2 weeks prior to the Treatment Day (Day 1)\].~4. Active, uncontrolled connective tissue disease.~5. Renal failure as defined by serum creatinine \> 220 µmol/L.~6. Liver function tests that are \> 2.0 times Upper Limit Normal.~7. Poor nutritional status as measured by serum albumin \< 30 g/L.~8. Active cancer or a history of cancer in the 5 years prior to signing the informed consent form (history of basal cell carcinoma is allowed).~9. Active wound infection (i.e. recent onset of erythema, oedema, and increased temperature of the foot with normal radiographs).~10. Diabetic Charcot neuroarthropathy or other structural deformity that would prevent adequate off-loading of the study foot.~11. Treatment with any systemic corticosteroid immunosuppressive chemotherapeutic agent, antiviral, or previous/current radiation therapy to lower extremity to be treated within 30 days prior to signing the informed consent form.~12. Having received another investigational drug or biologic within 30 days prior to signing the informed consent form or currently participating in an investigational drug or biologic study.~13. A psychiatric condition or chronic alcohol or drug abuse problem, determined from the patient's medical history, which in the Investigator's opinion may pose a threat to patient compliance.~14. History of non-compliance with treatment or clinical visit attendance (i.e. this study requires that patients will comply with the protocol and ulcer care regimen).~15. Any unstable medical condition judged by the Principal Investigator that would cause the study to be detrimental to the patient.~16. Wounds caused primarily by untreated vascular insufficiency, or where patients are primarily eligible for vascular intervention to promote wound healing.~17. Wounds with an aetiology not related to diabetes.~18. More than three wounds on the target lower extremity.~19. The wound to be studied not anatomically distinct from another wound(s) (separated by \< 1 cm from another wound or would interfere with standard of care treatment of another wound. Only one single wound per one study subject can be treated in this study.~20. Wounds which decrease in area by \> 50% during the screening 4-week run-in period.~21. Ulcers with underlying osteomyelitis on the leg with the wound to be treated.~22. Patients presenting with the clinical characteristics of cellulitis at the wound site (suppurative inflammation involving particularly the subcutaneous tissue, often mild erythema, tenderness, malaise, chills and fever).~23. Revascularization surgery on the leg with the wound to be treated ≤8 weeks prior to signing the informed consent form.~24. Surgery to lengthen Achilles tendon on the leg with the wound to be treated ≤8 weeks prior to signing the informed consent form.~25. Necrosis, purulence, or sinus tracts that cannot be removed by debridement on foot to be treated.~26. Received dermal substitute or living skin equivalent within 30 days prior to signing the informed consent form.~27. Received prior (Regranex®/becaplermin) therapy within 30 days prior to signing the informed consent form.~28. Has known history of clinical sensitivity reactions to products of bovine origin or to the primary or secondary dressings used in the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- mesenchymal stromal cells (Type: OTHER): mesenchymal stromal cells in collagen scaffold

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues